US review of countries' intellectual property policies under fire at first public hearing
This article was originally published in Scrip
The United States Trade Representative's review of its trading partners' intellectual property provisions came under fire from NGOs at the first ever 301 public hearing held recently. They argued that the USTR was undermining US procurement of low cost antiretrovirals (ARVs) as well as its commitment to the Doha Declaration regarding access to medicines.
You may also be interested in...
Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.
In an exclusive interview with the Pink Sheet, senior NICE director Meindert Boysen reveals the best advice he ever received and how companies whose products are under review can improve their chances of success.
UK HTA body NICE is looking to the future and rethinking its approach to data and how they inform its guidance.